Definium Therapeutics Inc (DFTX) Q2 2024 earnings summary

Executive summary

• Advanced MM120 into pivotal phase III trials for GAD after a successful end-of-phase II FDA meeting, with the first trial (VOYAGE) to start in H2 2024 and a second (PANORAMA) in H1 2025; expansion into MDD with EMERGE phase III to begin in H1 2025.

• MM120 received FDA Breakthrough Therapy Designation for GAD in March 2024 and reported strong phase IIb efficacy and safety data, including a 48% remission rate at 12 weeks post-dose.

• Raised over $75 million in recent public offerings, with total equity investments since early 2024 exceeding $250 million, extending cash runway into 2027.

• MM402 (R(-)-MDMA) is progressing through phase I trials for autism spectrum disorder, with results to inform further development.

• New U.S. patent extends MM120 ODT IP protection through 2041.

Financial highlights

• Cash and cash equivalents were $243.1 million as of June 30, 2024, up from $99.7 million at year-end 2023.

• Net loss for Q2 2024 was $5.9 million, down from $29.1 million in Q2 2023, mainly due to changes in warrant fair value.

• R&D expenses for Q2 2024 were $14.7 million, nearly flat year-over-year.

• General and administrative expenses fell to $9.8 million from $14.4 million year-over-year, mainly due to lower professional fees.

• Net cash used in operating activities for H1 2024 was $36.6 million, compared to $27.2 million in H1 2023.

Outlook and guidance

• Cash runway expected to last into 2027, at least 12 months beyond the first phase III GAD readout.

• Anticipate R&D expenses to increase in H2 2024 and 2025 as phase III trials ramp up.

• Phase III trials: VOYAGE (GAD) to start H2 2024, PANORAMA (GAD) and EMERGE (MDD) in H1 2025; topline data expected: VOYAGE in H1 2026, PANORAMA and EMERGE in H2 2026.